About Neurocrine

Our Company

Neurocrine Biosciences, Inc. of San Diego discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.

The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and NBI-98854 (Valbenazine) a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.

Research and Development Programs

Neurocrine’s Research Group continues to advance novel small molecule compounds into clinical development. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. Our scientists possess the skills and experience necessary to bring compounds from basic research concepts to drug candidate stage. Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine’s chemists, pharmacologists and biologists strive to create new solutions to unmet medical problems.

Neurocrine Biosciences Corporate Information

The Company’s common stock is traded on the Nasdaq Global Select Market System under the symbol “NBIX”

Contact Information
Jane Sorensen
Investor Relations
Telephone: (858) 617-7600

Neurocrine Biosciences
12780 El Camino Real
San Diego, CA 92130
Telephone: (858) 617-7600
Fax: (858) 617-7602